H.R. 1375 · 118th Congress (2023–2025)
EFFECTIVE Act
This bill specifies that the Food and Drug Administration may deny an application for a new opioid analgesic drug (i.e., opioid medication) upon a determination that the drug does not provide a significant advantage with respect to safety or effectiveness as compared to other drugs.
Show official title
To allow the Secretary of Health and Human Services to deny approval of a new drug application for an opioid analgesic drug on the basis of such drug not being clinically superior to other commercially available drugs.
Expired in House committee
Derived from the legislative history, not an official disposition.
Latest actionReferred to Health
This bill’s path
This is H.R. 1375’s recorded path, not a universal congressional workflow.
How bills become lawAll actionsIntroduced
Passed House
Passed Senate
Sent to President
Signed into law
Expired
- Sponsor
- Rep. David J. Trone (D-MD-6)
- Cosponsors
5 cosponsors
1 original · 4 later
- Rep. Daniel Meuser (R-PA-9)· Original · Mar 3, 2023
- Rep. Ann M. Kuster (D-NH-2)· Later · Mar 23, 2023
- Rep. Daniel T. Kildee (D-MI-8)· Later · Mar 27, 2023
- Rep. Josh Harder (D-CA-9)· Later · Apr 13, 2023
- Rep. Brittany Pettersen (D-CO-7)· Later · Jun 20, 2023
- Policy area
- Health
On this page
Timeline
i
In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.
Introduced in House
Document: Introduced in House
Sources
- Congress.gov actionIntro-H
- Library of Congress
- Latest
▸ 2 committee actions · Mar 3, 2023 – Mar 10, 2023
Referred to committee
Referred to the House Committee on Energy and Commerce.
Sources
- Congress.gov action
- House floor actions
Referred to Health
Referred to the Subcommittee on Health.
Sources
- Congress.gov action
- House committee actions
Expired
Introduced → Referred to House Health → No further action before the 118th Congress ended.
Committees
Text & titles
i
Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.
| Version | Date | Links |
|---|---|---|
| Introduced in House |
Titles (3)
EFFECTIVE Act
Display title, Short title · Introduced in House
Ensuring the FDA Fully Examines Clinical Trial Impact and Vitalness before Endorsement Act
Short title · Introduced in House
To allow the Secretary of Health and Human Services to deny approval of a new drug application for an opioid analgesic drug on the basis of such drug not being clinically superior to other commercially available drugs.
Official title · Introduced in House